Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study
← catalyst calendarNCT07347379 · readout ≤ 42 d
Sponsored by RxSight, Inc. (industry) · RXST — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
108estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-13 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Aphakia Cataract
Intervention
- Device: Light Adjustable lens (LAL) and Light Delivery Device (LDD)
Primary outcomes
what the primary-completion date above is the date OFMean absolute manifest refraction spherical equivalent (|MRSE|) at the Long-Term follow up visit
measured Up to 55 months
Mean manifest cylinder at the Long-Term follow up visit
measured Up to 55 months
Permalink · RXST's whole pipeline · Catalyst calendar · Every registered study · What changed